Do the risks of preimplantation genetic testing for aneuploidy outbalance the benefits?
Autor: | Paul Devroey, Sebastian Grewe, Klaus Diedrich |
---|---|
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
medicine.medical_specialty Pregnancy 030219 obstetrics & reproductive medicine medicine.diagnostic_test business.industry Reproductive medicine Obstetrics and Gynecology Aneuploidy medicine.disease Bioinformatics 03 medical and health sciences Human reproduction Polar body 030104 developmental biology 0302 clinical medicine medicine SNP business Comparative genomic hybridization Genetic testing |
Zdroj: | Der Gynäkologe. 52:667-672 |
ISSN: | 1433-0393 0017-5994 |
DOI: | 10.1007/s00129-019-4488-5 |
Popis: | Much has been achieved in the field of preimplantation genetic testing for aneuploidy (PGT-A; previously preimplantation genetic screening, PGS) in recent years, particularly with the novel and more precise methods for analyzing biopsied cells such as comparative genomic hybridization (CGH) and single-nucleotide polymorphism (SNP) arrays. Although these methods have been used in individual studies and shown an improvement in pregnancy and birth rates in some cases, the final results from prospective randomized studies are still awaited. Until these are available, the promising results from individual studies remain experimental. We also owe it to our patients to apply promising novel methods outside of studies, if a positive effect has been demonstrated. The same applies to the polar body diagnosis (PBD) practiced in Germany for aneuploidy screening. Thus, one can conclude that neither PGT-A by means of analyzing blastomeres nor polar body screening to indirectly investigate oocytes currently have a positive effect on pregnancy and birth rates. The large specialist societies, the American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE), also advise against routine use of these methods. |
Databáze: | OpenAIRE |
Externí odkaz: |